We are experts in myeloma…
it’s all we do

 

Our singular focus on myeloma ensures that we bring unparalleled expertise and dedication to everything we do

 

From actionable insights to strategic engagement with leading KOLs and community clinicians, our full suite of  services empowers you to lead in the myeloma market

Everything you need to navigate the myeloma market

Engagements

MYBOARD is a new format for Advisory Boards.

In place of single company events, MYBoard is an independent full day advisory board fully managed by MYELOMA360, with four 2-hour time slots for multiple companies, allowing for a focused, efficient, dedicated session to generate insights around your strategic objectives.

Insights

MYinSIGHTS provides real-time insights to data being presented at conferences or from the latest publications. Gain an understanding of how the experts view the data.

MYConference Targeted Reports. Collecting insights at medical conferences shouldn’t be hard. MYELOMA360 makes it easy

Strategy & Consulting

We are a team of seasoned biopharmaceutical specialists dedicated to helping companies strategize and plan their marketing, clinical development and medical affairs activities.

Our expertise is focused in myeloma across the full development lifecycle, allowing us to provide tailored solutions to drive your company’s success.

Everything you need to navigate the myeloma market

Latest insights

Myeloma News

Aurigene Oncology Limited announces promising results of Phase 1 study for India’s first trial for novel autologous CAR-T cell therapy for multiple myeloma

Source: Pharmacy Times articles This marks India’s first trial for a novel autologous BCMA directed CAR-T cell therapy in patients with relapsed/refractory multiple myeloma. Read More

Daratumumab-Based Regimen Shows Efficacy in All Patients With Multiple Myeloma, Regardless of Cytogenic Risk

Source: Pharmacy Times articles The benefits of the daratumumab-based regimen were seen in all patients, including those with high and standard cytogenic risk levels. Read More

Recent Publications

Imaging aspects of maxillomandibular bone alterations in patients with multiple myeloma treated with bisphosphonates: A systematic review

Imaging Sci Dent. 2024 Sep;54(3):221-231. doi: 10.5624/isd.20240032. Epub 2024 Jul 17. ABSTRACT...

Outcomes in Randomized Controlled Trials of Therapeutic Interventions for Multiple Myeloma: a Systematic Review

Crit Rev Oncol Hematol. 2024 Oct 3:104529. doi: 10.1016/j.critrevonc.2024.104529. Online ahead of...

Quadruplet regimens for patients with newly diagnosed multiple myeloma: A systematic review and meta-analysis

Blood Adv. 2024 Sep 30:bloodadvances.2024014139. doi: 10.1182/bloodadvances.2024014139. Online...

Multiple myeloma clinical trials exclude patients with the highest-risk disease: a systematic review of trial exclusion criteria

Leuk Lymphoma. 2024 Sep 24:1-10. doi: 10.1080/10428194.2024.2395440. Online ahead of print....

Risk assessment and clinical implications of COVID-19 in multiple myeloma patients: A systematic review and meta-analysis

PLoS One. 2024 Sep 6;19(9):e0308463. doi: 10.1371/journal.pone.0308463. eCollection 2024. ABSTRACT...

Email

info@myeloma360.com